Market Place
Sourcing Support
UCB bangs drum for epilepsy drug in videos ‘sound of profound’ seizure reduction
19 Jun 2024 //
FIERCE PHARMA
UCB takes on Jazz in severe epilepsy with new Fintepla label approval
29 Mar 2022 //
PHARMAPHORUM
Zogenix To Present New Long-term Data on FINTEPLA in Lennox-Gastaut Syndrome
04 Mar 2022 //
GLOBENEWSWIRE
Zogenix Provides Corporate Update and Reports Q4 and Full-Year Financial Results
28 Feb 2022 //
GLOBENEWSWIRE
Controversial opioid Zohydro ER pulled from the market
02 Feb 2022 //
ENDPTS
UCB to buy Zogenix for nearly $2B in `first step` for M&A in 2022
20 Jan 2022 //
BIOPHARMADIVE
Zogenix Submits NDA for FINTEPLA (Fenfluramine) in Japan
21 Dec 2021 //
GLOBENEWSWIRE
Zogenix Submits Type II Variation Application to (EMA) to the Use of FINTEPLA
20 Dec 2021 //
GLOBENEWSWIRE
Zogenix Reports Granting of Inducement Awards
16 Dec 2021 //
GLOBENEWSWIRE
Zogenix to Host Key Opinion Leader Webinar on Thymidine Kinase MT-1621
01 Nov 2021 //
GLOBENEWSWIRE
Zogenix Submits Supplemental New Drug Application for FINTEPLA®
28 Sep 2021 //
GLOBENEWSWIRE
Horizon, Jazz, Zogenix are buys at BofA despite threat of copycats
19 Sep 2021 //
SEEKINGALPHA
Zogenix Reports Granting of Inducement Awards
16 Sep 2021 //
GLOBENEWSWIRE
Zogenix Receives Orphan Drug Designation for FINTEPLA (Fenfluramine) in Japan
26 Aug 2021 //
GLOBENEWSWIRE
Zogenix Reports Granting of Inducement Awards
16 Aug 2021 //
GLOBENEWSWIRE
Zogenix Provides Corporate Update
05 Aug 2021 //
GLOBENEWSWIRE
Zogenix Second Quarter 2021 Financial Result , Host Conference Call and Webcast
22 Jul 2021 //
GLOBENEWSWIRE
Zogenix Second Quarter 2021 Financial Result , Host Conference Call and Webcast
22 Jul 2021 //
GLOBENEWSWIRE
Zogenix Product FINTEPLA Recognized for Setting a New Standard Dravet Syndrome
21 Jul 2021 //
GLOBENEWSWIRE
Pfizer, Zogenix, Catalyst, Rigel raise prices to start July
01 Jul 2021 //
FIERCEPHARMA
Zogenix to Participate in Two Upcoming Investor Conferences
21 Jun 2021 //
GLOBENEWSWIRE
Zogenix Provides Corporate Update and Reports First Quarter 2021
06 May 2021 //
GLOBENEWSWIRE
Zogenix Launches Global Access Program for FINTEPLA® (Fenfluramine)
27 Apr 2021 //
PRESS RELEASE
Zogenix Presents New Data at Virtual AAN 2021 Showing Improved Executive
22 Apr 2021 //
GLOBENEWSWIRE
Zogenix Presents New Data from a Study Highlighting the Impact FINTEPLA®
16 Apr 2021 //
BIOSPACE
Zogenix introduces Fintepla oral solution in Germany for treatment of seizures
01 Feb 2021 //
PHARMABIZ
Tevard Biosciences, Zogenix collaborate to identify and develop novel
06 Dec 2020 //
PHARMABIZ
A new RNA partnership hunts rare epilepsies; AbbVie and I-Mab tackle CD47
05 Dec 2020 //
ENDPTS
Tevard & Zogenix Announce Collaboration to Advance Novel Gene Therapies
04 Dec 2020 //
PRNEWSWIRE
Zogenix and Leading Experts to Present New Rare Epilepsy Data at AES 2020
02 Dec 2020 //
GLOBENEWSWIRE
Zogenix Presents New Data for FINTEPLA® in Dravet Syndrome at CNS 2020
15 Oct 2020 //
PRESS RELEASE
Zogenix, Inc. Announces Closing of Exercise by Initial Purchasers of Option
05 Oct 2020 //
GLOBENEWSWIRE
Zogenix Presents New Data at the World Muscle Society Conference 2020
03 Oct 2020 //
GLOBENEWSWIRE
Zogenix proposes $200M debt offering
22 Sep 2020 //
SEEKING ALPHA
Zogenix`s Fintepla successful in third pivotal study in severe type of epilepsy
09 Sep 2020 //
SEEKINGALPHA
Zogenix`s Fintepla ready to challenge GW Pharma in rare epilepsy
26 Jun 2020 //
FIERCEPHARMA
After 2 delays, Zogenix nabs FDA approval for epilepsy drug, setting GW Pharma
26 Jun 2020 //
ENDPTS
FDA pushes back decision on Zogenix epilepsy drug
28 Feb 2020 //
BIOPHARMADIVE
Another hiccup for GW`s seizure drug rival, Zogenix discloses FDA review delay
27 Feb 2020 //
ENDPTS
The Lancet Publishes Ph 3 Trial Results for Zogenix Drug FINTEPLA
17 Dec 2019 //
GLOBE NEWSWIRE
Zogenix buys Modis for $250M, building out rare disease pipeline
27 Aug 2019 //
BIOPHARMADIVE
Zogenix Ready to Resubmit Fintepla for Rare Epilepsy to FDA
27 Jun 2019 //
BIOSPACE
Encoded Therapeutics bags $104M to propel `precision gene therapy’
26 Jun 2019 //
FIERCE BIOTECH
Zogenix data blunder trips up FDA filing for epilepsy drug Fintepla
09 Apr 2019 //
FIERCE BIOTECH
FDA snubs Zogenix’s anti-seizure drug, not happy with some sloppy R&D work
09 Apr 2019 //
ENDPTS
Zogenix Announces Initial Quality of Life & Cognitive From Ph3 Trial of ZX008
27 Apr 2018 //
GLOBENEWSWIRE
Zogenix wins inside track at FDA with childhood epilepsy ‘breakthrough’
07 Feb 2018 //
ENDPTS
Zogenix Brings About Rivalry For Rare Epilepsy Drug
03 Oct 2017 //
SEEKINGALPHA
Zogenix stock soars on epilepsy drug trial successS
30 Sep 2017 //
REUTERS
Zogenix rockets up as PhIII study offers impressive data on Dravet syndrome
29 Sep 2017 //
ENDPTS
Zogenix Receives Orphan Drug Designation in the European Union for ZX008 in Lennox Gastaut Syndrome
05 Mar 2017 //
FINANCE YAHOO
Zogenix receives US patent entitled “Method for treatment of Dravet Syndrome”
01 Feb 2017 //
PHARMABIZ
Senate Response to Opioid Abuse Could Hit FDA, Drugmakers
28 Jan 2016 //
BLOOMBERG
FDA Seeks More Information on Zogenix`s Phase III Study of ZX008
20 Oct 2015 //
BIOSPACE
Purdue hones abuse-deterrent edge with painkiller safety campaign
22 Aug 2015 //
FIERCE PHARMA MARKETING
Up and Down the Ladder: The Latest Comings and Goings at Zogenix, Sanofi and…
17 Jul 2015 //
PHARMALOT
Zogenix Jettisons Controversial Pain Med Zohydro for $100M-Plus
11 Mar 2015 //
FIERCE PHARMA
Pharma Equities Under the Scanner - Pfizer, Sanofi, Eli Lilly, AstraZeneca, and Zogenix
02 Feb 2015 //
MARKET WATCH
